TGN-1062 / TGen - LARVOL DELTA

Targeting RNA Modification and Mitochondrial Metabolism Crosstalk in Leukemic Stem Cells with CDK7 Inhibitor TGN-1062. (PubMed, Blood Adv) - No abstract available

Journal

TGN-1062, a dual CDK7 and FLT3 Inhibitor, shows potent anti-AML activity and synergizes with Venetoclax (AACR 2024) - "Since its approval venetoclax, a BCL2 inhibitor, has been the standard treatment for older patients in combination with a hypomethylating agent (HMA), such as azacitidine or decitabine, with a 76% complete response (CR). Targeting CDK7 with TGN-1062 in combination with venetoclax or an HMA is a promising therapeutic approach for treatment of AML and needs further investigation."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CDK7 • MYC

Inhibition of CDK7 using small molecule inhibitor, TGN-1062, augments the effect of cisplatin treatment in head and neck PDX models (AACR 2023) - "While there are some successful treatments, like use of cetuximab in patients with EGFR expressing tumors, there is still a major unmet need in this area. Targeting CDK7 with TGN-1062 in combination with SOC therapy is a promising approach for treatment of HNSCC. TGN-1062 is a potent CDK7 inhibitor with potential for clinical development."

IO biomarker • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • BCL2 • CDK7 • EGFR

TGN-1062 inhibits CDK7 and augments the effects of gemcitabine and nab-paclitaxel in pancreatic cancer models (AACR 2022) - "Our potent and selective small molecule inhibitor of CDK7, TGN-1062, shows promise in pancreatic cancer models as a single or in combination with SOC . Preliminary data suggests that TGN-1062 can be developed further in multiple cancer indications."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Gastrointestinal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • BCL2 • CASP3 • CDK7 • MYC

[VIRTUAL] Preclinical studies with TGN-1062, a selective and reversible small molecule inhibitor of CDK7 (AACR 2021) - "TGN-1062 is a novel, selective, and reversible inhibitor of CDK7 and has significant antitumor activity in vivo. TGN-1062 is a potent CDK7 inhibitor with potential for clinical development."

IO biomarker • Preclinical • Acute Myelogenous Leukemia • Lung Cancer • Neuroendocrine Tumor • Oncology • Ovarian Cancer • Small Cell Lung Cancer • Solid Tumor • BAX • BCL2 • CDK7 • MCL1 • MYC